Jump to content

Vaxart COVID-19 vaccine

From Wikipedia, the free encyclopedia

Vaxart COVID-19 vaccine
Vaccine description
TargetSARS-CoV-2
Vaccine typeViral vector
Clinical data
Other namesVXA-CoV2-1, VXA-CoV2-1.1-S, VXA-CoV2-3.1
Routes of
administration		Oral
Identifiers
CAS Number

Vaxart COVID-19 vaccine is a COVID-19 vaccine candidate developed by Vaxart.[2][3][4] It is an enteric-coated tablet vaccine that can be administered orally.[5]

References

[edit]
  1. ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
  2. ^ Clinical trial number NCT04563702 for "Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults" at ClinicalTrials.gov
  3. ^ Clinical trial number NCT05067933 for "Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine (VXA-NVV-104)" at ClinicalTrials.gov
  4. ^ Clinical trial number NCT05067933 for "A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine" at ClinicalTrials.gov
  5. ^ Braun MR, Flitter BA, Sun W, Tucker SN (October 2023). "An easy pill to swallow: oral recombinant vaccines for the 21st century". Current Opinion in Immunology. 84 102374. doi:10.1016/j.coi.2023.102374. PMID 37562075.
logo
Scholia has a profile for Vaxart COVID-19 vaccine (Q110269782).
Retrieved from "https://en.wikipedia.org/w/index.php?title=Vaxart_COVID-19_vaccine&oldid=1314558104"